The FDA has awarded breakthrough device designation to Hemex Health’s rapid diagnostic test for sickle cell disease and beta ...
Sea of Remnants' Wanderer test is live, letting players set sail in their very own puppet pirate adventure till February 12th ...
The company’s test volume also increased by approximately 17% during the same period. In collaboration news, Natera and Exelixis announced a joint effort on a phase 3 trial for colorectal cancer ...
Following these results, Canaccord Genuity reiterated its Buy rating for Natera, maintaining a price target of $285.00. Additionally, Natera announced a collaboration with Exelixis on a phase 3 trial ...
This innovative approach will enhance the Signatera MRD test by integrating various data types, including circulating tumor DNA and digital pathology imaging. Furthermore, Natera’s Signatera test ...
Lastly, a study published in JAMA Oncology demonstrated that Natera’s Signatera test was used to detect MRD in colorectal cancer patients, showing improved survival when treated with celecoxib ...
Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results